Cardiovascular mortality · people with CKD requiring dialysis
1 finding from 1 review
Cardiovascular mortality · heart failure with chronic kidney disease
ACUTE: Serelaxin showed no clear difference in cardiovascular death compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular mortality · heart failure with chronic kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · preventing bone disease in kidney transplant recipients
It is very uncertain whether vitamin D changes cardiovascular death compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Cardiovascular mortality · preventing bone disease in kidney transplant recipients
It is very uncertain whether bisphosphonate changes cardiovascular death compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Cardiovascular mortality · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · people with diabetes and kidney disease
1 finding from 1 review
All cardiovascular death · people with chronic kidney disease requiring dialysis
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower death (cardiovascular) compared with control (placebo or standard care) (moderate certainty).
1 finding from 1 review
All cardiovascular death · heart failure with chronic kidney disease
CHRONIC: ACEi or ARB showed no clear difference in cardiovascular death ( compared with placebo (low certainty).
1 finding from 1 review
All cardiovascular death · heart failure with chronic kidney disease
CHRONIC: Beta‐blockers may leads to lower cardiovascular death ( compared with placebo (low certainty).
1 finding from 1 review
All cardiovascular death · people with diabetes and CKD
1 finding from 1 review
All cardiovascular death · people with diabetes and CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All cardiovascular death · people with diabetes and CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All cardiovascular death · people with diabetes and CKD
1 finding from 1 review
Cardiovascular mortality · people with diabetes and kidney disease
It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes cardiovascular death Median compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Cardiovascular mortality · people with diabetes and kidney disease
Angiotensin receptor blockers showed no clear difference in cardiovascular death Median compared with placebo or no treatment (low certainty).
1 finding from 1 review
Cardiovascular mortality · people with CKD (including HD and PD)
It is very uncertain whether hypoxia‐inducible factor (HIF) stabilisers changes cardiovascular death Median compared with placebo (very low certainty).
1 finding from 1 review